2022 Year in Review: Our Key Achievements
2022 has been a special and meaningful year for Samsung Bioepis which has seen significant achievements and celebration of its 10th anniversary. As we approach the end of 2022 and head into 2023, we would like to take this time to look back on some of our best moments and achievements we have made together.
A Decade of Innovation
On February 28th, we celebrated the 10th anniversary of our company’s establishment by reflecting the past, present and the future of our commitment and passion in increasing patient access to life-enhancing biologic medicines. Now as a team of over 900 colleagues, our President and Chief Executive Officer Christopher Hansung Ko shared a letter of gratitude for our dedicated colleagues and pledged to stay committed to our core values to expand access to healthcare.
Our Ophthalmology Firsts
At the beginning of the year, our ophthalmology biosimilar gained approval in Canada, becoming the first and only ranibizumab biosimilar to receive regulatory approval across North America. This shows our ongoing endeavor to accelerate our ophthalmology biosimilar development and expand therapeutic areas. On top of that, our ophthalmology biosimilar became commercially available from July 1 in the United States. We will continue to bring better access to biologic treatments by leveraging our experience in developing and manufacturing.
Two ISO Certifications
In September, we have attained two ISO certifications: ISO 14001 for Environmental Management System and ISO 50001 for Energy Management System in a step closer to our sustainable business goal. Samsung Bioepis is engaged in various environmental management activities at each step of value chain by reducing greenhouse gas emissions and waste (air pollutants, hazardous chemicals and etc.), by efficiently managing energy consumption (water, electricity, gas and etc.) and by applying eco-friendly measures in packaging and shipping (e.g. reducing product package size, using recyclable materials). We will continue to enhance and strengthen our sustainability management across our business activities.
Company of the Year – Asia – Pacific
Wrapping up our year in review on a positive note, we won ‘Company of the Year, Asia-Pacific’ at the ‘Global Generics & Biosimilars Awards 2022,’ in November which was held in Frankfurt, Germany. This year, we have been recognized for our best practice and setting new milestones as a leading company within the biosimilar industry.
Looking ahead to 2023, Samsung Bioepis will continue to build on these momentums and strive for innovation to enhance the lives of patients across the world through our pioneering and innovative use of science and technology.